BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/30/2025 10:57:29 AM | Browse: 446 | Download: 1216
Publication Name World Journal of Gastrointestinal Surgery
Manuscript ID 106361
Country China
Received
2025-02-25 03:58
Peer-Review Started
2025-02-25 03:58
First Decision by Editorial Office Director
2025-03-13 23:22
Return for Revision
2025-03-15 13:43
Revised
2025-03-28 19:35
Publication Fee Transferred
2025-04-02 14:32
Editorial Processing by Scientific Editor
2025-05-13 02:36
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2025-05-13 03:46
Articles in Press
2025-05-13 03:46
Edit the Manuscript by Language Editor
Typeset the Manuscript
2025-05-24 04:35
Publish the Manuscript Online
2025-05-30 10:57
ISSN 1948-9366 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer
Manuscript Source Unsolicited Manuscript
All Author List Qiu-Xian Chen, Yong-Bin Zhang, Wei-Ming Zeng, Yi-Chen Cai, Chen-Bin Lv, Ming-Qiao Lian, Rong-Jie Huang, Ming-Jie Lian, Wei-Long Lian, Qian-Hui Xu, Yu-Qin Sun and Li-Sheng Cai
ORCID
Author(s) ORCID Number
Qiu-Xian Chen http://orcid.org/0000-0003-0166-969X
Chen-Bin Lv http://orcid.org/0000-0003-0840-6868
Li-Sheng Cai http://orcid.org/0009-0003-6720-9896
Funding Agency and Grant Number
Funding Agency Grant Number
Wu Jieping Medical Fund No. 320.6750.2022-09-14
The climbing Fund of PhD workstation, Zhangzhou Affiliated Hospital of Fujian Medical University No. PDB202412
Corresponding Author Li-Sheng Cai, Chief Physician, Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, No. 59 West Shengli Road, Zhangzhou 363000, Fujian Province, China. wxccls2024@163.com
Key Words Gastric cancer; Neoadjuvant therapy; Immune checkpoint inhibitor; Efficacy; Safety
Core Tip This study investigated sintilimab (an immune checkpoint inhibitor) plus nab-paclitaxel and S-1 as neoadjuvant therapy for locally advanced gastric cancer. The combination significantly improved pathological complete response and major pathological response rates, while also demonstrating superior 2-year disease-free survival compared to chemotherapy alone, without additional safety concerns. These findings support its potential as an effective preoperative treatment strategy for locally advanced gastric cancer.
Publish Date 2025-05-30 10:57
Citation

Chen QX, Zhang YB, Zeng WM, Cai YC, Lv CB, Lian MQ, Huang RJ, Lian MJ, Lian WL, Xu QH, Sun YQ, Cai LS. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. World J Gastrointest Surg 2025; 17(6): 106361

URL https://www.wjgnet.com/1948-9366/full/v17/i6/106361.htm
DOI https://dx.doi.org/10.4240/wjgs.v17.i6.106361
Full Article (PDF) WJGS-17-106361-with-cover.pdf